؉ cell selected autologous transplantation in multiple myeloma (MM), we have performed a retrospective case-controlled analysis comparing 21 MM patients receiving high-dose melphalan and autologous transplantation with CD34
Introduction
High-dose chemotherapy followed by autologous transplantation yields a complete remission (CR) rate round 40% in patients with newly diagnosed multiple myeloma (MM). [1] [2] [3] However, despite longer disease-free and overall survival, all patients eventually relapse. Peripheral blood stem cells (PBSC) are currently the main source of autograft in patients with MM. 4 However, these transplants are proved to be contaminated by clonal cells that may contribute to relapse. [5] [6] [7] A way to reduce the risk of tumor cell contamination in the peripheral blood harvests is through positive CD34 ϩ progenitors selection. Indeed, positive selection of CD34 ϩ cells reduces the contamination of myeloma cells from the apheresis products up to 2 to 4 logs and provides a progenitor cell suspension capable of restoring normal hematopoiesis. [8] [9] [10] [11] [12] [13] [14] In order to evaluate the clinical impact of CD34 ϩ cell selected peripheral blood stem cell autologous transplantation in MM, we performed a case controlled analysis. 21 
Patients and methods

Patients
An attempt to perform CD34 ϩ stem cell selection has been made in 37 patients with newly diagnosed MM. Efficient CD34 ϩ selection of the apheresis products has been performed in 29 of them (78%). Of these 29 patients, 21 entered a program of single autologous transplantation with high-dose melphalan and CD34
ϩ selected products as front-line treatment. In a retrospective analysis, we compared these 21 patients with 21 controls treated during the same period of time with autotransplantation using unmanipulated PBSC. All patients have been selected from the Nantes myeloma database and treated in our centre. The two groups were matched for the following three criteria: age at diagnosis (р or Ͼ60 years), ␤2 microglobulin value at diagnosis (р or Ͼ2.5 mg/dl) and disease status at the time of transplantation. Table 1 shows the baseline characteristics of the 42 patients. No significant differences were found between the treatment groups.
Induction regimen and stem cell mobilization
All 42 patients received a median of three courses of VAD regimen (vincristine 0.4 mg days 1-4, doxorubicine 9 mg/m 2 days 1-4, dexamethasone 40 mg days 1-4). Peripheral blood stem cell (PBSC) were mobilized by a 6-day course of G-CSF (Neupogen; Amgen, Paris, France) at a dose of 600 g/day subcutaneously. PBSC were harvested on day 5, 6 and 7 after the beginning of G-CSF administration (CS3000 Baxter, Munich, Germany). In the CD34 ϩ group, the first two leukapheresis products were pooled and subjected to positive selection of CD34 ϩ cells as described below. The positive selection of CD34 ϩ cells was performed only when the first two leukapheresis products contained at least 2 ϫ 10 6 CD34 ϩ cells/kg. The third leukapheresis product, as well as the CD34 depleted fraction were kept frozen as back-ups.
Positive selection of CD34
ϩ stem cells
The methods were described in a previous report. 15 Briefly, mononuclear cells were incubated with a biotinylated anti-CD34 monoclonal antibody for 25 min, washed in PBS (Baxter) and passed over a computer-driven avidin immunoaffinity column device (CEPRATE stem cell concentrator system: CellPro, Bothell, WA, USA). Adsorbed CD34 ϩ cells were removed from the column by mechanical agitation, washed in PBS, resuspended in 9 ml PBS and frozen in the presence Hb, hemoglobin; Ca, calcemia; Creat, creatinine; ␤2mic, ␤2micro-globuline; CRP, C-reactive protein; HDM, high-dose melphalan; NS, non-significant. of 7.5% dimethylsulphoxyde, 4% human serum albumin, 10 U/ml heparin and stored at Ϫ196°C.
Pretransplant preparative regimen and supportive care
Conditioning pretransplant regimens were delivered according to three protocols of intensive therapy of the Intergroupe Français du Myélome IFM90, IFM94, IFM95-02, ie 8-Gy fractionated total body irradiation and 140 mg/m 2 melphalan, 140 or 200 mg/m 2 melphalan alone 2, 16, 17 (Table 1) . Thawed CD34 ϩ selected or unselected stem cells were reinfused 48 h after the end of high-dose therapy. All patients were treated in protected environment with HEPA and positive-pressure ventilation. Transfused blood products were not screened for cytomegalovirus antibody but were leukocyte-depleted using filters. Transfusions were administered to maintain the hemoglobin level over 8 g/dl and platelet count over 20 ϫ 10 9 /l. Fever during the neutropenic phase was treated with broadspectrum antibiotics and amphotericin as necessary. Granulocyte colony-stimulating factor (5 g/kg/day) was given intravenously in all cases from day 7 after transplantation until granulocyte counts exceeded 0.5 ϫ 10 9 /l for at least 2 consecutive days.
Response criteria
Complete remission (CR) was defined as the absence of a paraprotein on serum and urine electrophoresis and 5% or fewer plasma cells with normal morphologic features in a bone marrow aspirate (the absence of paraprotein was not confirmed in all cases by immunofixation). A return from low to normal levels of polyclonal immunoglobulins was not included in the definition. Very good partial response (VGPR) was defined as a 90% decrease of the serum paraprotein level; partial response (PR) as a 50% decrease of the serum paraprotein level and a 90% decrease of Bence-Jones protein; stable disease (SD) as no change in the paraprotein level; progressive disease (PD) as a 25% increase of the serum paraprotein level after two cycles of the initial chemotherapy; and relapse as paraprotein reappearance, bone marrow infiltration recurrence (which was evaluated every 6 months) in a patient with a complete response, or both, and a 50% increase in paraprotein above the 'plateau' level in two samples obtained 4 weeks apart in a patient with a response.
Statistical analysis
Response rates were compared by the chi-squared test. Quantitative values were compared by the Wilcoxon rank-sum test. The duration of event-free survival (EFS) was calculated for all patients from the date of transplantation to disease progression, relapse, death, or the date the patient was last known to be in remission. Overall survival (OS) was defined as the time from transplantation to death or last visit. Actuarial survival curves were plotted after the Kaplan-Maier method and differences between the curves were analyzed with the logrank test.
Cost analysis of the stem cell collection procedure
In each group, the estimate cost of the stem cell collection was calculated on a per patient basis and was provided by the Cellular Therapy Unit where stem cell collections were processed. The calculation included the cost of the following parameters: cytapheresis bags, quality control of the products (including CD34 ϩ cell numeration), technical work time, and cryopreservation. Moreover, in the CD34 ϩ group, cost of the selection procedure itself was evaluated.
Results
Stem cell collection, CD34
ϩ cell purification and hematologic recovery (Table 2) The median number of leukaphereses required for patients in the selected and control arms was the same. The median num-
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؉ stem cell autologous transplantation in MM N Morineau et al 1817 ber of CD34 ϩ cells in the leukapheresis product before processing was equivalent in both groups (data not shown). Patients in the selected group had significantly fewer CD34 ϩ cells/kg infused (median 2.2; range 0.5-14.30) than patients in the control group (median 9.4; range 1.1-15) (P Ͻ0.001). Moreover, the number of patients receiving at least 2 ϫ 10 6 CD34/kg was significantly higher in the control group (18/21) as compared to the selected group (11/21) (P ϭ 0.045).
Median times to neutrophil engraftment (neutrophils у 0.5 × 10 9 /l were 10 days (range 7-16) and 9.5 (range 4-50) in the CD34 ϩ selected and control groups, respectively (P ϭ 0.357). The median times to platelet count Ͼ20 ϫ 10 9 /l were 9 days (range 4-28) and 4.5 days (range 1-40) in the CD34 ϩ selected and unselected cohorts, respectively (P ϭ 0.005). Median numbers of platelet and red blood cell transfusions were three (range 0-9) and four (range 0-10) in the selected group and 1.5 (range 0-10) and one (range 0-10) in the control group, respectively (P ϭ NS).
Toxicity
No transplant-related mortality was observed in the group receiving unselected products. On the other hand, in the CD34 ϩ selected group, one patient died from Pseudomonas aeruginosa septicemia. Another patient experienced a cytomegalovirus interstitial pneumonitis successfully treated with intravenous gancyclovir and reinfusion of the unselected back-up product to improve T cell recovery. No other severe opportunistic infection has been reported over the 6-month post-transplantation period in the CD34 ϩ group.
Response rate, event-free survival and overall survival
Response rates to high-dose therapy were not statistically different in both groups: 18 patients in the selected arm were considered as responders after transplantation (85.7%) as compared to 19 patients (90.4%) in the control group. The number of patients in CR or VGPR was 16 in the CD34 ϩ group
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Figure 1
Probabilities of event-free survival for patients with MM undergoing autologous PBSC with or without CD34 ϩ cell selection and 10 in the control group (P ϭ NS). The OS at 36 months was not statistically different in both groups, 85% in the selected group as compared to 79% in the control arm (P ϭ 0.27). The EFS was not statistically different in both groups, 32% in the selected group vs 39% in the control group (P ϭ 0.67) (Figure 1 ). Table 3 illustrates the estimates of cost of the stem cell collection procedure according to criteria described in Materials and methods on a per patient basis. The average cost per patient in the unselected group amounted to approximately US $1685 as compared to approximately US $6270 in the CD34 ϩ group, which implies a cost reduction of 73% when using unselected products. The increased cost of stem cell processing in the selected group was mainly related to the price of the immunoaffinity column and to the longer technical time required for the purification. 
Cost analysis (Table 3)
Discussion
In the present study, we have retrospectively compared a group of newly diagnosed MM patients undergoing autologous CD34 ϩ selected PBSC transplantation with a group of patients receiving unselected products as part of front-line therapy. The present study allows three main conclusions. First, we confirm both the feasibility of CD34-positive selection using G-CSF priming alone.
15 CD34 ϩ cell selection was effective in 29 out of 37 cases (78%) of patients with newly diagnosed MM. In most previously published works, mobilization of stem cells was obtained with cyclophosphamide and G-CSF. [11] [12] [13] [14] 18 This myelosuppressive procedure potentially exposed patients to infectious complications and required hospitalization. Although the number of CD34 ϩ cells collected appears to be superior after priming with high-dose cyclophosphamide followed by G-CSF as compared to G-CSF alone, [19] [20] [21] [22] G-CSF alone in steady-state allowed efficient stem cell mobilization especially when performed in slightly pretreated patients and with responsive disease at the time of mobilization. Both conditions were present for most patients in our study. The main advantage of collecting PBSC after priming with G-CSF alone are to reduce the risks and the costs of the procedure and to avoid hospitalization. In this study, hematopoietic recovery was satisfactory. All patients receiving CD34 ϩ selected PBSC achieved sustained engraftment. The neutrophil recovery was comparable in both groups despite the lower number of CD34 ϩ cells reinfused in the selected group. On the contrary, platelet engraftment was significantly delayed in the CD34 ϩ group, which is consistent with previously published data. 12, 14, 23 The infused cell dose of CD34 ϩ cells has been described to influence post-transplant engraftment. Vescio et al 12 have reported that patients who received less than 2 ϫ 10 6 CD34 ϩ cells/kg were at increased risk for a delay in the time of platelet recovery. Our own study confirms these findings. In addition, CD34
+ cell selection raises the issue of delayed immunological reconstitution. Though increased incidence of severe viral infections have not yet been reported in previous studies of autologous transplantation with CD34 + progenitor cells in MM, 12,14,23 a significant T cell defect has clearly been described after such transplantations. 12, 24 Although the case of cytomegalovirus pneumonitis described in this report may be incidental, assessment of functional immune reconstitution after CD34 + cell selected PBSC requires further evaluation.
Secondly, in our report, there is no evidence that CD34 + -selected PBSC transplantation allows a better outcome as compared with unselected autologous procedure. In the nonrandomized study reported by Gupta et al, 14 20 patients with MM were transplanted with CD34 + -selected products and compared to 16 patients receiving unselected products. No difference in EFS was observed between the groups. Gandhi et al 23 performed a case-controlled analysis in which 15 patients who underwent autologous CD34 + -selected PBSC transplantation were compared to 15 matched controls. Again, the 3-year probability of EFS and OS in the selected group was similar to that of the unpurged group. Recently, in a controlled randomized trial comparing the use of CD34 + -selected vs unselected peripheral blood autografts for transplantation 12 , there was also no apparent difference between the two treatments with respect to EFS and OS but analysis was only performed at 1 year post-transplant. Although our study was not randomized and included a relatively low number of patients, we have analyzed two homogeneous cohorts of patients. Indeed, case matching was made on three parameters which have been identified as main pronostic factors for outcome in MM: age and ␤2-microglobulin value at diagnosis and disease status at the time of transplantation. Moreover, all patients received identical induction chemotherapy and conditioning regimens before transplantation. We have found that the response rates after high-dose therapy were not statistically different in either group. Event-free survival and OS at 3 years were comparable and similar to that previously reported.
2 Thus, our disappointing results seem to confirm previously published ones.
Proof of effective tumor reduction through CD34 + progenitor selection as assessed by molecular analysis of minimal residual disease has been repeatedly given but selected samples often remained contaminated with malignant cells. 9, [12] [13] [14] 18 Since EFS and OS in the group of patients receiving selected grafts do not seem to be improved as compared to the group of patients receiving unselected products, it may be that the purge obtained by the CD34
+ cell selection alone is not still sufficient. Purification of the graft through the selection of primitive CD34 + Thy1 + Lin − stem cells allows a depletion of myeloma cells to undetectable levels. 25 However, previous clinical trials in MM have reported lack of engraftment in some patients receiving Thy1
+ cells and substantially delayed hematopoietic restoration when compared to the reinfusion of untreated PBSC. 26, 27 More recently, Lemoli et al 28 reported a double-step purging procedure through positive selection of CD34 + cells and subsequent removal of CD10
+ and CD56 + cells based on the phenotypic characteristics of tumor cells. This procedure reduced tumor cell contamination below the lower limit of detection of molecular analysis. In this report, transplantation with CD34 + B-lin − cells was associated with a rapid and sustained hematopoietic recovery. However, in MM, the clinical role of graft purge to prevent disease relapse remains questionable and the interest of double-step purging procedures should be evaluated in randomized trials.
Finally, we have shown that CD34 selection was associated with a 73% increase in the cost of stem cell collection calculated on a per patient basis. With the premise that both therapies are equivalent, it seems that unselected PBSC use is more cost-effective for autologous transplantation in MM than CD34 + -selected PBSC one. In conclusion, our study confirms that G-CSF alone is effective to collect PBSC in sufficient number for positive CD34 + -selection in newly diagnosed MM patients. Nevertheless, this cumbersome and expensive autotransplantation procedure does not seem to result in an improvement in EFS and OS in newly diagnosed MM patients. Randomized studies comparing CD34 + -selected and unselected PBSC are underway in the USA and Europe. While awaiting the final results of these studies, unselected PBSC which is less expensive and easier to process than CD34 + -selected PBSC, should be reasonably prefered.
Perhaps after reading this article, scientists can concentrate on more useful studies such as finding antigens specific to the MM cells and specifically removing those cells, while leaving both the CD34 + and CD34 − stem cells in the graft. This paper, assessing such large numbers of patients with a 3-year followup, should convince clinicians and researchers that alternative purging strategies must be developed.
